Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status
Mankind Pharma's ANDA for Rosuvastatin Calcium has been granted Abbreviated Approval (AP) status by the FDA.
Published: August 5, 2026
Updated: August 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Statin
Company: Mankind Pharma
Asset: Rosuvastatin
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mankind Pharma
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of Abbreviated Approval status to Mankind Pharma for Rosuvastatin Calcium signifies increased competition in the statin market. This could lead to pricing pressures and market share shifts for existing players in the cardiovascular therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Mankind Pharma's Rosuvastatin Calcium.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.